All In Biotech

Drug Trial Radar · NCT04083599

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

350

Actual

Start

Sep 17, 2019

Primary completion

Dec 30, 2025

Study completion Jan 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.

Conditions

  • Malignant Solid Tumor
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • GEN1042Biological

    Intravenous

  • PembrolizumabDrug

    Intravenous

  • CisplatinDrug

    Intravenous

  • CarboplatinDrug

    Intravenous

  • 5-FUDrug

    Intravenous

  • GemcitabineDrug

    Intravenous

  • Nab paclitaxelDrug

    Intravenous

  • PemetrexedDrug

    Intravenous

  • PaclitaxelDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation and Safety Run-in Parts: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: First Cycle (21 days)
  2. Dose Expansion: Objective Response Rate (ORR)Time frame: Up to approximately 2 years and 4 months

Locations

76 sites in 12 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Cancer & Blood Specialty Clinic

    Los Alamitos, California

  • Moores Cancer Center at the UC San Diego Health

    San Diego, California

  • Yale University Cancer Center

    New Haven, Connecticut

  • ChristianaCare

    Newark, Delaware

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Florida Cancer Affiliates

    Ocala, Florida

  • Hope and Healing Cancer Services

    Hinsdale, Illinois

  • University of Kentucky

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Maryland Oncology Hematology PA

    Columbia, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Levine Cancer Center

    Charlotte, North Carolina

  • Novant Health Cancer Institute - Forsyth (Medical Oncology)

    Winston-Salem, North Carolina

  • Kaiser Permanente (KP) Oncology/Hematology

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Lumi Research

    Kingwood, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Virgina Cancer Specialists

    Fairfax, Virginia

  • Adventist Health System/Sunbelt,Inc

    Seattle, Washington

  • Medical Oncology Associates, PS

    Spokane, Washington

  • Rigshospitalet (Copenhagen University Hospital)

    Copenhagen, Denmark

  • Herlev University Hospital

    Herlev, Denmark

  • University Hospital of Southern Denmark, Vejle Hospital

    Vejle, Denmark

  • Centre hospitalier Universitaire de Bordeaux

    Bordeaux, France

  • Centre Antoine Lacassagne

    Nice, France

  • Gustave Roussy

    Villejuif, France

  • ARENSIA Research Clinic at the Research Institute of Clinical Medicine

    Tbilisi, Georgia

  • Nationales Centrum fr Tumorerkrankungen NCT

    Heidelberg, Germany

  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH

    Ludwigshafen, Germany

  • Department of Dermatology, University of Mainz

    Mainz, Germany

  • Universitätsmedizin Mannheim Dermatologie

    Mannheim, Germany

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany

  • Rabin Medical Center

    Petah Tikva, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Azienda Ospedaliera Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliera S.Croce e Carle Cuneo

    Cuneo, Italy

  • Istituto Nazionale dei Tumori

    Milan, Italy

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.